Natera Organ Health

For the latest news and updates from #Natera, follow @NateraGenetics.

Today is #PKDAwarenessDay, learn more from @PKDFoundation below. 💙

It was a packed house at our #WTC2025 industry symposium, Beyond Biopsy: Cell-free DNA Use Not Just for Ruling Out Rejection. Thank you to our panelists Dr. Nicolae Leca, Dr. Anthony Langone, Alex Rogers, Dr. Gaurav Gupta and to everyone who attended. #Natera @ASTSChimera @AST_info @ttsorg

See you at #WTC2025, where #Natera will have 16 abstracts spanning our organ health offerings in kidney, heart and lung. This includes 5 oral presentations, showcasing several high-impact datasets. One presentation we're looking forward to is the landmark PEDAL study, which was recently published in the American Journal of Transplantation. This first-of-its-kind, prospective multi-center trial demonstrated Prospera Kidney’s ability to predict long-term outcomes following organ rejection. Meet us at booth #1002 to explore the technology behind #Prospera and connect with our team. RSVP here ➡️ ow.ly/Hwwp50WyIwy for these exclusive experiences: • Behind-the-scenes lab tours at our Bay Area site • A product theater in collaboration with American Kidney Fund Read more about our presentations here: ow.ly/cx1v50WyIwx #TransplantInnovation #PersonalizedMedicine @ASTSChimera @AST_info @ttsorg

👉 Check out the recording of @NateraNeph's #ISHLT2025 industry symposium to learn more about dd-cfDNA in #LungTx rejection monitoring + how elevated #ProsperaLung tests may lead to important clinical insights for complex patients. 🫁💡📽️ 🔗: ishlt.org/about/news-det…

Check out this #ISHLTVoices podcast episode, presented by @NateraNeph, on the evolution of #ddcfDNA testing and noninvasive rejection monitoring post-#HeartTransplantation. 🫀 🎧 LISTEN NOW at 🔗 bit.ly/4lnW9K2, Spotify, Apple Podcasts 🎧 #DQS #ProsperaHeart

🌎 Natera’s 2024 Sustainability Report is now live! This report reflects the efforts of teams across Natera to help reduce environmental impact, support our communities and foster a culture of belonging, while expanding access to our technology for more patients than ever before. ow.ly/xuRB50Wg4sH #Natera

❤️ One year of progress ❤️ One year of partnership ❤️ One year of Prospera Heart with DQS Learn more: ow.ly/8MOP50Wb3pu

Today, we celebrate fathers and father figures in all their forms. From guiding hands to quiet support, from hard-earned wisdom to unconditional encouragement, fatherhood shows up in countless ways. Some are dads by biology, others by choice. All leave a lasting impact. To the fathers, stepfathers, mentors, and role models: thank you. What you do matters, every single day. Happy Father's Day! 💙💚 #FathersDay #Fatherhood #ThankYouDads

It’s a time to celebrate life, share hope, and recognize the incredible strength of those living with and beyond cancer. Whether you’re reflecting on your own survivorship or standing beside a loved one, today is about connection, resilience, and community. At Natera, we’re proud to support cancer survivors—including our own colleagues, their families, and the patients we serve—through continued innovation in cancer care. To learn how communities across the country are marking this day, visit @SurvivorsDay: ow.ly/OLkR50W29s1 #CancerSurvivors #NCSD2025 #CancerAwareness #Survivorship

Join our webinar, Implementing Prospera - Advantages of our Natera Concierge Program, to learn more about: • Common questions when switching brands or starting a new workflow • Resources Natera can provide to your team • Our Natera Concierge Team 👉ow.ly/CqKl50VY2Yy

We’re also presenting how integrating real-world data with renal genetic test results reveals chronic kidney disease and treatment journeys in patients with autosomal dominant Alport syndrome. #ISPORAnnual #RenalGenetics

Exciting results from the DEFINE-HT study: Prospera Heart with donor quantity score (DQS) significantly correlates with clinical outcomes after heart transplantation and outperforms biopsy in predicting graft dysfunction. The prospective, multicenter DEFINE-HT study—the first of its kind—demonstrated that elevated donor-derived cell-free DNA (dd-cfDNA) is associated with an increased risk of adverse events such as treated rejection, graft dysfunction, re-transplantation, and death. Key findings: • Elevated dd-cfDNA tripled the prediction of graft dysfunction compared to biopsy • Patients with an elevated dd-cfDNA result were significantly more likely to experience adverse outcomes (HR: 2.56, p=0.0299) • Prospera Heart with DQS showed a stronger correlation with clinical outcomes compared to donor fraction alone These findings were presented today at ISHLT 2025. DEFINE-HT advances our understanding of precision medicine in heart transplantation, emphasizing less invasive, more predictive approaches for better patient care. ow.ly/xLIZ50VK2Vq #ISHLT #Natera

Still feeling inspired by @ScotPollard31, heart transplant recipient and NBA champion, who gave a powerful speech at #ISHLT2025. We are always in awe of the resilience of those in the transplant community. #Natera #TransplantInnovation @ISHLT

Identifying the genetic cause of kidney disease can offer critical insights: it informs prognosis, guides treatment options, and enables appropriate family screening. kidneyfund.org/amkd-awareness… #APOL1Aware #KidneyHealth #GeneticTesting

Thank you, transplant nurses, for all that you do for the transplant community! #TransplantNurseWeek #Natera

🔬 This Lab Week, we’re celebrating the dedicated teams from laboratory operations across Natera. Our lab teams are the heart of Natera, never losing sight that there’s a person behind each sample. Because of their work, we were able to serve more than 2 million patients last year. We appreciate and celebrate their hard work and dedication. Thank you, lab teams, for your continued contributions to our mission! 💙💚 #LabWeek2025 #Natera

Being APOL1 aware means knowing how your genes impact your kidney health. Knowing whether you have the APOL1 variants that cause AMKD could keep your kidneys working longer. The only way to know is to have a genetic test. @KidneyFund #AMKDAwarenessDay ow.ly/3KZN50VjwbK

We're looking forward to seeing you at #ISHLT2025! Learn about our 10 abstracts, join our symposia on dd-cfDNA innovations in heart and lung transplantation, and stop by booth # 401 to connect! 📈🤝 ow.ly/H6n350VyYFi @ISHLT #TransplantCare #HeartLung #ddcfDNA #Natera

Celebrate #KidsTransplantWeek & #NPTW with Transplant Families & sponsor @nateragenetics! 🎉 Join the 2025 Pediatric Transplant Conference on Fri, April 25th (10 AM-5:30 PM EDT) to learn how to help pediatric recipients THRIVE ! Register: transplantfamilies.org/ptc2025 #PTC2025 #Natera